Cargando…

Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations

SIMPLE SUMMARY: Genomic driver alterations with potential impact on prognosis and treatment response are increasing in non-small cell lung cancer (NSCLC). However, few comprehensive data are available on tumor heterogeneity in all these specific subgroups. We conducted this research with the aim to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passaro, Antonio, Attili, Ilaria, Rappa, Alessandra, Vacirca, Davide, Ranghiero, Alberto, Fumagalli, Caterina, Guarize, Juliana, Spaggiari, Lorenzo, de Marinis, Filippo, Barberis, Massimo, Guerini-Rocco, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124171/ https://www.ncbi.nlm.nih.gov/pubmed/33946519 http://dx.doi.org/10.3390/cancers13092172

Ejemplares similares

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay
por: Fumagalli, Caterina, et al.
Publicado: (2022)

Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses
por: Fumagalli, Caterina, et al.
Publicado: (2020)

Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients
por: Fumagalli, Caterina, et al.
Publicado: (2019)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
por: Spitaleri, Gianluca, et al.
Publicado: (2023)

Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study
por: Guarize, Juliana, et al.
Publicado: (2021)

Making the Most of Complexity to Create Opportunities: Comprehensive Genomic Profiling and Molecular Tumor Board for Patients with Non-Small Cell Lung Cancer (NSCLC)
por: Fumagalli, Caterina, et al.
Publicado: (2021)

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
por: Attili, Ilaria, et al.
Publicado: (2022)

Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study
por: Casiraghi, Monica, et al.
Publicado: (2021)

Understanding EGFR heterogeneity in lung cancer
por: Passaro, Antonio, et al.
Publicado: (2020)

Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years’ Single-Institution Experience of 762 Consecutive Patients
por: Fumagalli, Caterina, et al.
Publicado: (2022)

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
por: Attili, Ilaria, et al.
Publicado: (2023)

The Impact of Multidisciplinary Team Meetings on Patient Management in Oncologic Thoracic Surgery: A Single-Center Experience
por: Petrella, Francesco, et al.
Publicado: (2021)

A role for the immune system in advanced laryngeal cancer
por: Tagliabue, Marta, et al.
Publicado: (2020)

Author Correction: A role for the immune system in advanced laryngeal cancer
por: Tagliabue, Marta, et al.
Publicado: (2021)

Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study
por: Casiraghi, Monica, et al.
Publicado: (2023)

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
por: Spitaleri, Gianluca, et al.
Publicado: (2023)

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review
por: Valenza, Carmine, et al.
Publicado: (2021)

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy
por: Fumagalli, Caterina, et al.
Publicado: (2019)

Long-term clinical outcomes and prognostic factors of upfront surgery as a first-line therapy in biopsy-proven clinical N2 non-small cell lung cancer
por: Bertolaccini, Luca, et al.
Publicado: (2022)

Circulating and tissue biomarkers in early-stage non-small cell lung cancer
por: Fumagalli, Caterina, et al.
Publicado: (2017)

Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
por: Petrella, Francesco, et al.
Publicado: (2023)

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
por: Spitaleri, Gianluca, et al.
Publicado: (2015)

Incorporating atezolizumab in the adjuvant setting of non-small cell lung cancer: key discussion points from an expert multidisciplinary panel by Italian Association of Thoracic Oncology
por: de Marinis, Filippo, et al.
Publicado: (2022)

The Genetic and Immunologic Landscape Underlying the Risk of Malignant Progression in Laryngeal Dysplasia
por: Chu, Francesco, et al.
Publicado: (2023)

In EBUS Signo Vinces: New Indications in Thoracic Oncology for Mediastinal Lymph Node Staging Using Endobronchial Ultrasound
por: Guarize, Juliana, et al.
Publicado: (2022)

Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients
por: Rinaldi, Lisa, et al.
Publicado: (2023)

Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features
por: Passaro, Antonio, et al.
Publicado: (2021)

Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model
por: de Marinis, Filippo, et al.
Publicado: (2020)

A proposal for a postoperative protocol for the early diagnosis of bronchopleural fistula after lung resection surgery
por: Bertolaccini, Luca, et al.
Publicado: (2021)

Testing for COVID-19 in lung cancer patients
por: Passaro, A., et al.
Publicado: (2020)

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
por: Lin, Ruiting, et al.
Publicado: (2021)

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%
por: Attili, Ilaria, et al.
Publicado: (2022)

A case of Warthin-like papillary thyroid carcinoma with diffuse sclerosing stroma and a novel RET mutation: a new entity or a combined tumour?
por: Maffini, Fausto, et al.
Publicado: (2019)

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
por: Yang, James Chih-Hsin, et al.
Publicado: (2022)

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
por: Del Re, Marzia, et al.
Publicado: (2019)

Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer
por: Galetta, Domenico, et al.
Publicado: (2022)

Upfront Advanced Radiotherapy and New Drugs for NSCLC Patients with Synchronous Brain Metastases: Is the Juice Worth the Squeeze? A Real-World Analysis from Lombardy, Italy
por: Corrao, Giulia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4a3gdbpd3r82kmm5adba8e5db2